Switch theme
Sign up to access all valuation multiples
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company’s products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
2020
269
Last FY Revenue $23.5M
Last FY EBITDA $4.0M
$85.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Jin Medical International achieved revenue of $23.5M and an EBITDA of $4.0M.
Jin Medical International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jin Medical International valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $23.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $9.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 40% | XXX | XXX | XXX |
| EBITDA | XXX | $4.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 17% | XXX | XXX | XXX |
| EBIT | XXX | $3.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | 15% | XXX | XXX | XXX |
| Net Profit | XXX | $3.7M | XXX | XXX | XXX |
| Net Margin | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | $3.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Jin Medical International's stock price is $1.
Jin Medical International has current market cap of $100M, and EV of $85.0M.
See Jin Medical International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $85.0M | $100M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Jin Medical International has market cap of $100M and EV of $85.0M.
Jin Medical International's trades at 3.6x EV/Revenue multiple, and 21.3x EV/EBITDA.
Equity research analysts estimate Jin Medical International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jin Medical International's P/E ratio is not available.
See valuation multiples for Jin Medical International and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $100M | XXX | $100M | XXX | XXX | XXX |
| EV (current) | $85.0M | XXX | $85.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 21.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 23.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 27.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -36.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJin Medical International's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $22K for the same period.
Jin Medical International's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jin Medical International's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jin Medical International and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $22K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jin Medical International acquired XXX companies to date.
Last acquisition by Jin Medical International was XXXXXXXX, XXXXX XXXXX XXXXXX . Jin Medical International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jin Medical International founded? | Jin Medical International was founded in 2020. |
| Where is Jin Medical International headquartered? | Jin Medical International is headquartered in United States of America. |
| How many employees does Jin Medical International have? | As of today, Jin Medical International has 269 employees. |
| Who is the CEO of Jin Medical International? | Jin Medical International's CEO is Mr. Erqi Wang. |
| Is Jin Medical International publicy listed? | Yes, Jin Medical International is a public company listed on NAS. |
| What is the stock symbol of Jin Medical International? | Jin Medical International trades under ZJYL ticker. |
| When did Jin Medical International go public? | Jin Medical International went public in 2023. |
| Who are competitors of Jin Medical International? | Similar companies to Jin Medical International include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Jin Medical International? | Jin Medical International's current market cap is $100M |
| Is Jin Medical International profitable? | Yes, Jin Medical International is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
